Key facts
- Complement Therapeutics’s last known valuation is $8.1M (Feb 2022).
- It has raised $84.1M; the latest was Later Stage VC in Oct 2025.
- Notable investors include Venrock, Forbion, MaasInvest, Panakes Partners, Cambridge Innovation Capital — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Complement Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Complement Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Complement Therapeutics
Developer of a biotechnology platform designed to treat chronic diseases driven by the dysregulation of the complement system. The company's platform aims to design a methodology that stratifies patients based on their complement-activation profile and offers a patient selection for future clinical trials, enabling patients to access improved medical treatment.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2020
- Employees
- 34
- Website
- complementtx.com/
- Ownership
- Privately Held (backing)
Complement Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Complement Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Complement Therapeutics in its N-PORT filings yet. We sweep new filings monthly.